Vaxcyte
↗San Carlos, California, USA
Vaxcyte Inc. is a clinical-stage biopharmaceutical company headquartered in San Carlos, California, focused on developing next-generation protein vaccines to prevent bacterial infectious diseases. The company utilizes an innovative cell-free protein synthesis platform called XpressCF to engineer high-fidelity vaccines with expanded serotype coverage. Vaxcyte's lead programs target invasive pneumococcal disease (IPD) and pneumonia caused by Streptococcus pneumoniae, positioning the company as a potential disruptor in the multi-billion-dollar pneumococcal vaccine market dominated by Pfizer's Prevnar franchise. The company has positioned itself as a 'David vs. Goliath' story in the biotech industry, developing vaccines that could significantly improve upon existing pneumococcal conjugate vaccines with broader serotype coverage and superior immunogenicity profiles.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$0M (pre-commercial stage)
Founded:2013
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO (IPO completed June 2020)
Total Raised:$283M (pre-IPO); additional capital raises of $2.2B+ through 2024 offerings
Investors:RA Capital Management, Janus Henderson Investors, TPG Growth, Abingworth LLP, Longitude Capital Management, Frazier Healthcare Partners, Pivotal bioVenture Partners, Medicxi, Roche Venture Fund, CTI Life Sciences Fund, Foresite Capital
STOCK
Exchange:NASDAQ
Ticker:PCVX
Market Cap:$5.88B - $10.22B (varies, as of late 2025)
PIPELINE
Stage:Clinical (Phase 2 and Phase 3)
Lead Drug Stage:Phase 3 (VAX-31 adult program)
Modalities:Pneumococcal Conjugate Vaccine (PCV), Protein-based Vaccine, Cell-free protein synthesis
Active Trials:3
Trial Phases:Phase 2: 2 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Lonza: Manufacturing partnership for global commercial production of pneumococcal conjugate vaccines at Visp, Switzerland facility with dedicated manufacturing suite, Sutro Biopharma: License agreement for XpressCF cell-free protein synthesis platform; manufacturing rights agreement for cell-free extract, Thermo Fisher Scientific: Agreement to expand domestic manufacturing capacity for future commercial production
COMPETITION
Position:Emerging challenger - positioned to disrupt Pfizer's dominant pneumococcal vaccine franchise with broader serotype coverage
Competitors:Pfizer (Prevnar 20, Prevnar 13), Merck (Capvaxive, Vaxneuvance, V116), GlaxoSmithKline (GSK) pneumococcal vaccines, Affinivax
LEADERSHIP
Key Executives:
Grant Pickering - CEO and Co-Founder
Andrew Guggenhime - President & CFO
Jim Wassil - EVP & COO
Mark Wiggins - Chief Business Officer (CBO)
Jeff Fairman - VP Research and Founder
Harpreet Dhaliwal - Chief Technical Operations Officer
Scientific Founders:Grant Pickering, Jeff Fairman
Board Members:Carlos Paya (Board Chair), Michael Kamarck (Board Member), Dr. Olivier Brandicourt (Board Member), John Furey (Board Member), Jacks Lee (Board Member), Kurt von Emster (Board Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Vaxcyte. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.